Exhibit 99.3
Reported Net Sales Revenue by Product ($ in 000's) * |
Avastin | Q1 | Q2 | Q3 | Q4 | Total | |||||
2011 | 1,597,461 | 1,582,705 | 1,581,095 | 1,469,994 | 6,231,255 | |||||
2010 | 1,506,788 | 1,596,892 | 1,594,707 | 1,646,218 | 6,344,605 | |||||
2009 | 1,345,487 | 1,295,536 | 1,439,730 | 1,514,053 | 5,594,806 | |||||
2008 | 980,715 | 1,084,930 | 1,180,427 | 1,239,382 | 4,485,454 | |||||
2007 | 678,068 | 746,587 | 797,013 | 875,084 | 3,096,752 | |||||
2006 | 439,318 | 516,052 | 570,551 | 592,897 | 2,118,817 |
Herceptin | Q1 | Q2 | Q3 | Q4 | Total | |||||
2011 | 1,391,568 | 1,559,975 | 1,642,898 | 1,432,771 | 6,027,211 | |||||
2010 | 1,270,846 | 1,349,512 | 1,300,934 | 1,409,310 | 5,330,602 | |||||
2009 | 1,210,268 | 1,133,993 | 1,226,435 | 1,278,626 | 4,849,323 | |||||
2008 | 1,105,426 | 1,195,215 | 1,211,982 | 1,186,806 | 4,699,428 | |||||
2007 | 891,761 | 949,556 | 979,602 | 1,015,033 | 3,835,952 | |||||
2006 | 529,585 | 659,719 | 761,099 | 803,576 | 2,753,979 |
Lucentis | Q1 | Q2 | Q3 | Q4 | Total | |||||
2011 | 887,757 | 943,418 | 1,052,809 | 1,075,015 | 3,958,999 | |||||
2010 | 721,967 | 698,890 | 745,376 | 804,684 | 2,970,917 | |||||
2009 | 462,103 | 469,736 | 555,296 | 615,212 | 2,102,347 | |||||
2008 | 363,615 | 393,682 | 460,167 | 454,922 | 1,672,386 | |||||
2007 | 224,820 | 219,579 | 299,995 | 322,300 | 1,066,695 | |||||
2006 | - | - | 10,689 | 157,742 | 168,431 |
Xolair | Q1 | Q2 | Q3 | Q4 | Total | |||||
2011 | 267,754 | 277,642 | 310,874 | 314,911 | 1,171,182 | |||||
2010 | 228,859 | 225,878 | 251,055 | 263,389 | 969,179 | |||||
2009 | 184,669 | 181,086 | 211,006 | 219,693 | 796,454 | |||||
2008 | 137,875 | 169,521 | 177,179 | 183,753 | 668,329 | |||||
2007 | 129,172 | 130,700 | 144,250 | 147,754 | 551,876 | |||||
2006 | 95,241 | 99,354 | 112,608 | 118,002 | 425,204 |
Tysabri | Q1 | Q2 | Q3 | Q4 | Total | |||||
2011 | 329,696 | 356,876 | 388,758 | 381,618 | 1,456,948 | |||||
2010 | 293,047 | 287,925 | 293,664 | 316,657 | 1,191,292 | |||||
2009 | 221,854 | 229,993 | 257,240 | 285,481 | 994,569 | |||||
2008 | 129,430 | 163,076 | 200,783 | 233,070 | 726,359 | |||||
2007 | 30,468 | 48,715 | 71,972 | 94,521 | 245,675 | |||||
2006 | - | - | - | 7,890 | 7,890 |
Actemra | Q1 | Q2 | Q3 | Q4 | Total | |||||
2011 | 30,433 | 35,370 | 46,709 | 48,671 | 161,183 | |||||
2010 | 52,908 | 5,405 | 10,493 | 22,919 | 91,725 | |||||
2009 | 19,504 | 17,920 | 30,313 | 39,888 | 107,625 | |||||
2008 | 1,452 | 1,377 | 5,981 | 12,305 | 21,115 | |||||
2007 | - | - | - | 1,137 | 1,137 | |||||
2006 | - | - | - | - | - |
* As reported to PDL by its licensees | ||||||||||
Totals may not sum due to rounding |
Royalty Revenue by Product ($ in 000's) * |
Avastin | Q1 | Q2 | Q3 | Q4 | Total | |||||
2011 | 22,283 | 41,967 | 23,870 | 22,886 | 111,006 | |||||
2010 | 16,870 | 44,765 | 29,989 | 24,922 | 116,547 | |||||
2009 | 13,605 | 35,161 | 21,060 | 15,141 | 84,966 | |||||
2008 | 9,957 | 30,480 | 19,574 | 12,394 | 72,405 | |||||
2007 | 8,990 | 21,842 | 17,478 | 9,549 | 57,859 | |||||
2006 | 10,438 | 15,572 | 15,405 | 12,536 | 53,952 |
Herceptin | Q1 | Q2 | Q3 | Q4 | Total | |||||
2011 | 25,089 | 42,209 | 31,933 | 21,812 | 121,042 | |||||
2010 | 23,402 | 38,555 | 27,952 | 25,441 | 115,350 | |||||
2009 | 16,003 | 32,331 | 26,830 | 18,615 | 93,779 | |||||
2008 | 14,092 | 34,383 | 28,122 | 20,282 | 96,880 | |||||
2007 | 19,035 | 28,188 | 22,582 | 14,802 | 84,608 | |||||
2006 | 15,142 | 19,716 | 21,557 | 20,354 | 76,769 |
Lucentis | Q1 | Q2 | Q3 | Q4 | Total | |||||
2011 | 8,878 | 24,313 | 12,157 | 10,750 | 56,099 | |||||
2010 | 7,220 | 19,091 | 10,841 | 8,047 | 45,198 | |||||
2009 | 4,621 | 12,863 | 8,123 | 6,152 | 31,759 | |||||
2008 | 3,636 | 11,060 | 7,631 | 4,549 | 26,876 | |||||
2007 | 2,931 | 6,543 | 6,579 | 3,517 | 19,570 | |||||
2006 | - | - | 289 | 3,335 | 3,624 |
Xolair | Q1 | Q2 | Q3 | Q4 | Total | |||||
2011 | 4,590 | 7,621 | 5,916 | 5,823 | 23,949 | |||||
2010 | 3,723 | 6,386 | 4,980 | 4,652 | 19,741 | |||||
2009 | 2,665 | 5,082 | 4,085 | 3,722 | 15,553 | |||||
2008 | 1,488 | 4,866 | 3,569 | 2,927 | 12,850 | |||||
2007 | 1,684 | 3,942 | 3,332 | 2,184 | 11,142 | |||||
2006 | 2,263 | 2,969 | 3,041 | 2,495 | 10,768 |
Tysabri | Q1 | Q2 | Q3 | Q4 | Total | |||||
2011 | 9,891 | 10,796 | 11,588 | 11,450 | 43,725 | |||||
2010 | 8,791 | 8,788 | 8,735 | 9,440 | 35,754 | |||||
2009 | 6,656 | 7,050 | 7,642 | 8,564 | 29,912 | |||||
2008 | 3,883 | 5,042 | 5,949 | 6,992 | 21,866 | |||||
2007 | 839 | 1,611 | 2,084 | 2,836 | 7,370 | |||||
2006 | - | - | - | 237 | 237 |
Actemra | Q1 | Q2 | Q3 | Q4 | Total | |||||
2011 | 913 | 1,136 | 1,401 | 1,460 | 4,910 | |||||
2010 | 1,587 | 237 | 315 | 688 | 2,827 | |||||
2009 | 585 | 537 | 909 | 1,197 | 3,228 | |||||
2008 | 44 | - | 146 | 369 | 559 | |||||
2007 | 32 | - | - | 17 | 49 | |||||
2006 | - | - | - | - | - |
* As reported to PDL by its licensees |
Totals may not sum due to rounding |
Manufacturing Location & Sales - Genentech / Roche & Novartis ($ in 000's) * |
Avastin Sales | 2010 - Q3 | 2010 - Q4 | 2011 - Q1 | 2011 - Q2 | 2011 - Q3 | 2011 - Q4 | ||||||
US Made & Sold | 820,453 | 800,139 | 708,539 | 719,967 | 688,966 | 684,878 | ||||||
US Made & ex-US Sold | 338,929 | 415,576 | 580,981 | 548,710 | 587,975 | 375,830 | ||||||
ex-US Made & Sold | 435,325 | 430,503 | 307,941 | 314,028 | 304,155 | 409,286 | ||||||
Total | 1,594,707 | 1,646,218 | 1,597,461 | 1,582,705 | 1,581,095 | 1,469,994 | ||||||
US Made & Sold | 51% | 49% | 44% | 45% | 44% | 47% | ||||||
US Made & ex-US Sold | 21% | 25% | 36% | 35% | 37% | 26% | ||||||
ex-US Made & Sold | 27% | 26% | 19% | 20% | 19% | 28% |
Herceptin Sales | 2010 - Q3 | 2010 - Q4 | 2011 - Q1 | 2011 - Q2 | 2011 - Q3 | 2011 - Q4 | ||||||
US Made & Sold | 410,563 | 416,611 | 409,854 | 442,903 | 445,395 | 453,168 | ||||||
US Made & ex-US Sold | 306,085 | 425,303 | 423,053 | 642,670 | 495,086 | 612,908 | ||||||
ex-US Made & Sold | 584,286 | 567,396 | 558,661 | 474,402 | 702,416 | 366,695 | ||||||
Total | 1,300,934 | 1,409,310 | 1,391,568 | 1,559,975 | 1,642,898 | 1,432,771 | ||||||
US Made & Sold | 32% | 30% | 29% | 28% | 27% | 32% | ||||||
US Made & ex-US Sold | 24% | 30% | 30% | 41% | 30% | 43% | ||||||
ex-US Made & Sold | 45% | 40% | 40% | 30% | 43% | 26% |
Lucentis Sales | 2010 - Q3 | 2010 - Q4 | 2011 - Q1 | 2011 - Q2 | 2011 - Q3 | 2011 - Q4 | ||||||
US Made & Sold | 326,840 | 360,911 | 378,451 | 409,674 | 422,335 | 428,884 | ||||||
US Made & ex-US Sold | 418,536 | 443,773 | 509,307 | 533,745 | 630,474 | 646,131 | ||||||
ex-US Made & Sold | - | - | - | - | - | - | ||||||
Total | 745,376 | 804,684 | 887,757 | 943,418 | 1,052,809 | 1,075,015 | ||||||
US Made & Sold | 44% | 45% | 43% | 43% | 40% | 40% | ||||||
US Made & ex-US Sold | 56% | 55% | 57% | 57% | 60% | 60% | ||||||
ex-US Made & Sold | 0% | 0% | 0% | 0% | 0% | 0% |
Xolair Sales | 2010 - Q3 | 2010 - Q4 | 2011 - Q1 | 2011 - Q2 | 2011 - Q3 | 2011 - Q4 | ||||||
US Made & Sold | 165,109 | 170,001 | 164,621 | 167,608 | 184,837 | 188,728 | ||||||
US Made & ex-US Sold | - | - | - | - | - | - | ||||||
ex-US Made & Sold | 85,945 | 93,388 | 103,133 | 110,034 | 126,037 | 126,184 | ||||||
Total | 251,055 | 263,389 | 267,754 | 277,642 | 310,874 | 314,911 | ||||||
US Made & Sold | 66% | 65% | 61% | 60% | 59% | 60% | ||||||
US Made & ex-US Sold | 0% | 0% | 0% | 0% | 0% | 0% | ||||||
ex-US Made & Sold | 34% | 35% | 39% | 40% | 41% | 40% |
Total Sales | 2010 - Q3 | 2010 - Q4 | 2011 - Q1 | 2011 - Q2 | 2011 - Q3 | 2011 - Q4 | ||||||
US Made & Sold | 1,722,965 | 1,747,662 | 1,661,465 | 1,740,152 | 1,741,534 | 1,755,657 | ||||||
US Made & ex-US Sold | 1,063,551 | 1,284,652 | 1,513,340 | 1,725,125 | 1,713,535 | 1,634,869 | ||||||
ex-US Made & Sold | 1,105,556 | 1,091,287 | 969,735 | 898,464 | 1,132,608 | 902,165 | ||||||
Total | 3,892,072 | 4,123,601 | 4,144,540 | 4,363,741 | 4,587,677 | 4,292,691 | ||||||
US Made & Sold | 44% | 42% | 40% | 40% | 38% | 41% | ||||||
US Made & ex-US Sold | 27% | 31% | 37% | 40% | 37% | 38% | ||||||
ex-US Made & Sold | 28% | 26% | 23% | 21% | 25% | 21% |
* As reported to PDL by its licensees |
Totals may not sum due to rounding |